We are:

  • A Biotechnology Company Specializing in Human Vaccines
  • Creating, Developing, Manufacturing & Testing Innovative AIDS Vaccines
  • Conducting Multiple Site Phase 2 Human Clinical Vaccine Trial

Our AIDS Vaccines:

  • Are Designed for Predominant AIDS Virus Subtypes
  • Use DNA & Viral Vector Technologies
  • Satisfactorily Completed Phase 1 Human Clinical Trial Testing
  • Have Been Proven Safe & Have Demonstrated Ability To Stimulate Immune Responses

Key Market Factors:

  • Vaccines Are The Most Cost Effective Way to Combat Infectious Disease
  • Large Global AIDS Vaccine Market Is Estimated To Be More Than $4 Billion
  • Customer Base Includes All Ages, Genders, Races, Nationalities, Geographical Regions

08 February 2010

Clinical Trial Update

Read full story (pdf) »

02 February 2010

GeoVax to Present
at BIO CEO & Investor Conference

1PM EST, Tues., 09 Feb.
Read full story (pdf) »
View Webcast »

06 January 2010

Newman Appointed V.P., Research & Development

Read full story (pdf) »

01 December 2009

GeoVax Celebrates World AIDS Day With Continued Trial Progress

Read full story (pdf) »

IND Approval Process

Company Fact Sheet

S&P